Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIX5HF)

Drug Name

AAV2/8-LSPhGAA Drug Info

Synonyms

ACTUS 101

Indication

Disease Entry	ICD 11	Status	REF
Pompe disease	5C51.3	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Alpha-glucosidase (GLA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cipaglucosidase alfa	DMAPDH2	Glycogen storage disease type II	5C51.3	Approved in EU	[2]
Cipaglucosidase alfa	DMAPDH2	Glycogen storage disease type II	5C51.3	Approved in EU	[3]
Deoxynojirimycin	DM2ATZB	Pompe disease	5C51.3	Phase 3	[4]
Anamorelin	DM6HXTS	Carbohydrate metabolism disorder	5C51.Z	Phase 3	[5]
Maltose	DMH0ROP	N. A.	N. A.	Phase 1/2	[6]
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[7]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[7]
Double Oxidized Cysteine	DM6TU84	Discovery agent	N.A.	Investigative	[7]
POP-1	DMVTKCX	Solid tumour/cancer	2A00-2F9Z	Investigative	[8]
JBP-1	DM0KMPN	Solid tumour/cancer	2A00-2F9Z	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Alpha-glucosidase (GLA)	TTHCF4J	LYAG_HUMAN; GANAB_HUMAN; GANC_HUMAN	Not Available	[1]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03533673) AAV2/8-LSPhGAA in Late-Onset Pompe Disease. U.S. National Institutes of Health.
2	Cipaglucosidase Alfa: First Approval. Drugs. 2023 Jun;83(8):739-745.
3	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761204
4	Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
5	Absorption, elimination, and metabolism of CS-1036, a novel -amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.Drug Metab Dispos.2013 Apr;41(4):878-87.
6	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
7	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8	US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.